Fitch affirms Pfizer

Fitch Ratings said it affirmed Pfizer Inc.'s AAA senior unsecured debt rating and F1+ short-term debt ratings.

The outlook remains stable.

Pfizer's announcement of a definite merger agreement to purchase Vicuron Pharmaceuticals for about $1.9 billion in cash will have no impact on the credit ratings of the company, Fitch said.

Pfizer maintains superior liquidity through a very large cash balance and short-term investments of about $22 billion, a $12 billion commercial paper program, and $3 billion of unused lines of credit at the end of the first quarter of 2005.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.